Related Experiment Video

Updated: Oct 2, 2026

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

No evidence of platelet activation during atrial pacing in subjects with stable angina

M Bazzan, P Schinco, F Orzan

    Cardiologia (Rome, Italy)
    |March 1, 1989
    PubMed

    Insights

    This study investigated platelet activation in patients with ischemic heart disease during induced tachycardia. Researchers found no significant platelet activation in these patients compared to controls, suggesting tachycardia does not activate platelets in stable angina.

    Area of Science:

    • Cardiology
    • Hematology
    • Physiology

    Background:

    • Platelet activation is a key factor in thrombotic events, particularly in ischemic heart disease (IHD).
    • The effect of pacing-induced tachycardia on platelet behavior in patients with stable angina remains incompletely understood.
    • Understanding platelet response during tachycardia is crucial for managing IHD complications.

    Purpose of the Study:

    • To investigate platelet activation markers in patients with stable ischemic heart disease during pacing-induced tachycardia.
    • To compare platelet activation between IHD patients and a control group under similar conditions.
    • To determine if myocardial ischemia during tachycardia leads to measurable platelet activation.

    Main Methods:

    • Coronary angiography was used to confirm significant coronary artery narrowing in IHD patients.
    • Blood samples were collected from peripheral veins, coronary venous sinus, and ascending aorta.
    • Platelet activation markers, beta-thromboglobulin (beta-tg) and platelet factor 4 (PF4), were measured before and during atrial pacing.
    • Electrocardiogram (ECG) monitored heart rhythm during pacing-induced tachycardia.

    Main Results:

    • No significant differences in platelet activation markers (beta-tg, PF4) were observed between IHD patients and controls in peripheral venous blood.
    • No trans-myocardial gradient for platelet activation was detected in either group.
    • Platelet activation did not increase in IHD patients or controls during pacing-induced tachycardia.

    Conclusions:

    • Pacing-induced tachycardia does not appear to cause significant platelet activation in patients with stable ischemic heart disease.
    • The study did not find evidence of increased platelet aggregation or release of activation markers during tachycardia in this patient group.
    • Further research may be needed to explore platelet behavior in different cardiac conditions or during more sustained ischemic episodes.

    More Related Videos

    Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice08:05

    Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

    Published on: June 29, 2022

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

    Published on: July 21, 2023

    Related Concept Videos

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

    Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

    The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
    Angina II: Classification01:27

    Angina II: Classification

    Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
    Angina III: Clinical Manifestations and Assessment01:29

    Angina III: Clinical Manifestations and Assessment

    Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...